MSB 2022 - The road to commercialisation, page-13

You said the same stuff about otat mate. so sure novartis had some inside scoop and that's why they left. stick to the facts: NVS said the data was not sufficient to proceed with the agreement. NVS are pivoting away from covid treatments and back into non covid treatments. No guesswork here, this is what we know.
you are just saying they will likely not succeed more so than succeed because...? No reason provided, except you have dressed it up like a wise opinion: appealing to your own created sense of authority. I would guess that you are short for sure or have a desire to short (but I will admit thats only a baseless guess )